KR101012917B1 - 피롤 헵탄산 화합물의 신규한 결정형 - Google Patents

피롤 헵탄산 화합물의 신규한 결정형 Download PDF

Info

Publication number
KR101012917B1
KR101012917B1 KR1020080019764A KR20080019764A KR101012917B1 KR 101012917 B1 KR101012917 B1 KR 101012917B1 KR 1020080019764 A KR1020080019764 A KR 1020080019764A KR 20080019764 A KR20080019764 A KR 20080019764A KR 101012917 B1 KR101012917 B1 KR 101012917B1
Authority
KR
South Korea
Prior art keywords
formula
compound
crystalline form
alcohol
hydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020080019764A
Other languages
English (en)
Korean (ko)
Other versions
KR20080080959A (ko
Inventor
김문성
유무희
이재걸
김용직
박성진
최준호
성시영
임홍규
차대원
Original Assignee
동아제약주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 동아제약주식회사 filed Critical 동아제약주식회사
Priority to PCT/KR2008/001218 priority Critical patent/WO2008108572A1/en
Priority to JP2009552583A priority patent/JP2010520273A/ja
Priority to US12/449,867 priority patent/US7915302B2/en
Priority to CA002679317A priority patent/CA2679317A1/en
Priority to EP08723256A priority patent/EP2132171A4/en
Priority to RU2009136427/04A priority patent/RU2421445C1/ru
Publication of KR20080080959A publication Critical patent/KR20080080959A/ko
Application granted granted Critical
Publication of KR101012917B1 publication Critical patent/KR101012917B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
KR1020080019764A 2007-03-02 2008-03-03 피롤 헵탄산 화합물의 신규한 결정형 Active KR101012917B1 (ko)

Priority Applications (6)

Application Number Priority Date Filing Date Title
PCT/KR2008/001218 WO2008108572A1 (en) 2007-03-02 2008-03-03 Novel crystal forms of pyrrolylheptanoic acid derivatives
JP2009552583A JP2010520273A (ja) 2007-03-02 2008-03-03 ピロリルヘプタン酸誘導体の新規な結晶形態
US12/449,867 US7915302B2 (en) 2007-03-02 2008-03-03 Crystal forms of pyrrolylheptanoic acid derivatives
CA002679317A CA2679317A1 (en) 2007-03-02 2008-03-03 Novel crystal forms of pyrrolylheptanoic acid derivatives
EP08723256A EP2132171A4 (en) 2007-03-02 2008-03-03 NOVEL CRYSTALLINE FORMS OF PYRROLYLHEPTANOIC ACID DERIVATIVES
RU2009136427/04A RU2421445C1 (ru) 2007-03-02 2008-03-03 Новые кристаллические формы производных пирролилгептановой кислоты

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20070020999 2007-03-02
KR1020070020999 2007-03-02

Publications (2)

Publication Number Publication Date
KR20080080959A KR20080080959A (ko) 2008-09-05
KR101012917B1 true KR101012917B1 (ko) 2011-02-08

Family

ID=40020978

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020080019764A Active KR101012917B1 (ko) 2007-03-02 2008-03-03 피롤 헵탄산 화합물의 신규한 결정형

Country Status (8)

Country Link
US (1) US7915302B2 (enExample)
EP (1) EP2132171A4 (enExample)
JP (1) JP2010520273A (enExample)
KR (1) KR101012917B1 (enExample)
CN (1) CN101657419A (enExample)
CA (1) CA2679317A1 (enExample)
RU (1) RU2421445C1 (enExample)
WO (1) WO2008108572A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011219437A (ja) * 2010-04-14 2011-11-04 Towa Yakuhin Kk 結晶性形態ｔｗ−１のアトルバスタチンヘミカルシウム水和物とその製造方法
KR20120011249A (ko) 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
RU2555360C2 (ru) * 2012-11-06 2015-07-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ определения воды в координационных соединениях

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036384A1 (en) * 1999-11-17 2001-05-25 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
WO2002043732A1 (en) 2000-11-30 2002-06-06 Teva Pharmaceutical Industries Ltd. Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
WO2003070702A1 (en) 2002-02-15 2003-08-28 Teva Pharmaceutical Industries Ltd. Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
DE69634054T2 (de) * 1995-07-17 2005-12-08 Warner-Lambert Co. Kristalline (R-(R*, R*))-2-(4-Fluorophenyl)-β, δ-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-((Phenylamino)Carbonyl)-1H-Pyrrol-1-Heptancarbonsäure Hemi Calcium Salz (Atorvastatin)
DE19951107A1 (de) * 1999-10-23 2001-05-23 Zahnradfabrik Friedrichshafen Steuerung eines Automatgetriebes eines Kraftfahrzeuges
SI20425A (sl) * 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
EP1423364B1 (en) * 2001-06-29 2015-11-04 Warner-Lambert Company LLC Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
EP1562583A1 (en) * 2002-09-03 2005-08-17 Morepen Laboratories Ltd. Atorvastatin calcium form vi or hydrates thereof
CA2508871C (en) * 2002-11-28 2008-09-09 Teva Pharmaceutical Industries Ltd. Crystalline form f of atorvastatin hemi-calcium salt
WO2005090301A1 (en) * 2004-03-17 2005-09-29 Ranbaxy Laboratories Limited Crystalline form of atorvastatin hemi calcium
WO2006048894A1 (en) * 2004-11-05 2006-05-11 Morepen Laboratories Limited Novel crystalline forms of atorvastatin calcium and processes for preparing them.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036384A1 (en) * 1999-11-17 2001-05-25 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
WO2002043732A1 (en) 2000-11-30 2002-06-06 Teva Pharmaceutical Industries Ltd. Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
WO2003070702A1 (en) 2002-02-15 2003-08-28 Teva Pharmaceutical Industries Ltd. Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix

Also Published As

Publication number Publication date
RU2421445C1 (ru) 2011-06-20
EP2132171A1 (en) 2009-12-16
KR20080080959A (ko) 2008-09-05
US20100113556A1 (en) 2010-05-06
US7915302B2 (en) 2011-03-29
EP2132171A4 (en) 2010-11-17
CA2679317A1 (en) 2008-09-12
CN101657419A (zh) 2010-02-24
WO2008108572A1 (en) 2008-09-12
RU2009136427A (ru) 2011-04-10
JP2010520273A (ja) 2010-06-10

Similar Documents

Publication Publication Date Title
KR100389518B1 (ko) 결정질[r-(r*,r*)]-2-(4-플루오로페닐)-베타,델타-디히드록시-5-(1-메틸에틸)-3-페닐-4-[(페닐아미노)카르보닐]-1h-피롤-1-헵탄산헤미칼슘염(아토르바스타틴)
AU2002255479B2 (en) Crystalline forms VI and VII of atorvastatin clacium
BG108393A (bg) Кристални форми на[r-(r*,r*)]-2-(флуорофенил)-бета, делта-дихидрокси-5-(1-метилетил)-3-фенил-4-[(фениламино)карбонил]-1н-пирол-1-хептанова киселина калциева сол (2:1) (аторвастатин)
AU2002258092A1 (en) Crystalline forms of [R-(R*,R*)]-2-(4-Fluorophenyl)-BETA, DELTA-dihydroxy-5-(1-methylethyl)-3-Phenyl-4-[phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
AU2002255479A1 (en) Crystalline forms VI and VII of atorvastatin clacium
KR101012917B1 (ko) 피롤 헵탄산 화합물의 신규한 결정형
WO2005090301B1 (en) Crystalline form of atorvastatin hemi calcium
US7074818B2 (en) Crystalline forms VI and VII of Atorvastatin calcium
KR100878140B1 (ko) 아토바스타틴의 스트론튬염 또는 이의 수화물, 및 이를포함하는 약학 조성물
US10252993B2 (en) Crystalline form of atorvastatin hemi-calcium salt, hydrate thereof, and method of producing the same
US20090082421A1 (en) Crystalline Form B4 of Atorvastatin Magnesium and a Process Thereof
WO2006048894A1 (en) Novel crystalline forms of atorvastatin calcium and processes for preparing them.
JP2007505885A (ja) ［Ｒ−（Ｒ＊，Ｒ＊）］−２−（４−フルオロフェニル）−β，δ−ジヒドロキシ−５−（１−メチルエチル）−３−フェニル−４−［（フェニルアミノ）カルボニル］−１Ｈ−ピロール−１−ヘプタン酸の結晶性形態
KR20160117843A (ko) 결정형 및 이의 제조방법
KR101723783B1 (ko) 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
JPS61249970A (ja) 新規な置換２−（ｎ−アルキニル−ｎ−フエニルアミノ）イミダゾリン誘導体
KR920003604B1 (ko) 1-(2,5-디플루오로페닐)-3-퀴놀린 카르본산 유도체 및 그 제조방법
KR20110026831A (ko) 신규 결정형의 아토바스타틴 칼슘염 또는 이의 수화물

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

FPAY Annual fee payment

Payment date: 20131226

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20141211

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20151230

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20161222

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20171219

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

FPAY Annual fee payment

Payment date: 20191126

Year of fee payment: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 12

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 13

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 14

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 15

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 16